Mads Nybo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mads Nybo has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte Gils
Department of Clinical Biochemistry , Odense University Hospital , Odense , Denmark
5 shared publications - Ana-Maria Simundic
Department of Medical Laboratory Diagnostics, University Hospital ‘Sveti Duh’, 10000 Zagreb, Croatia
3 shared publications - Michael Peter Cornes
Biochemistry Department, Worcestershire Acute Hospitals NHS Trust, Worcester, UK
3 shared publications - Anne-Mette Hvas
Aarhus University Hospital
2 shared publications - Bo Abrahamsen
Research Unit OPEN, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Medicine 1, Holbæk Hospital, Holbæk, Denmark
2 shared publications - Giuseppe Lippi
Section of Clinical Biochemistry , University of Verona , Verona , Italy
2 shared publications
Latest Publications
- Open Access
- 3 April 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 86 (3) , 293-297
Recommendation on quality assurance of pneumatic transportation systems an opinion paper from the Nordic preanalytical scientific working group
From a cautious start at the beginning of this millennium [1–4], laboratory automation has expanded remarkably over the last two decades to most laboratories [5,6], leading to considerable improvem...
- 3 April 2026
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 86 (3) , 293-297
Open AccessRecommendation on quality assurance of pneumatic transportation systems an opinion paper from the Nordic preanalytical scientific working group
From a cautious start at the beginning of this millennium [1–4], laboratory automation has expanded remarkably over the last two decades to most laboratories [5,6], leading to considerable improvem...
- Open Access
- 30 March 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- Vol. 188 (14) , 1-6
Present and future use of point-of-care testing
The use of point-of-care testing (POCT) for patient-based biochemical measurements in blood is growing rapidly, and the number will likely increase dramatically outside hospitals in the coming years due to healthcare reform and pressure on various healthcare sectors. This literature review finds that it calls for attention to the analysis performance and its limitations, as well as with the skills of the equipment users (including citizens). The Danish Institute for Quality in Healthcare has recommended that national standards for the quality assurance of POCT be established, and we, as laboratories, would be happy to help identify which areas requires national standardisation.
- 30 March 2026
- Published by Danish Medical Association in Ugeskrift for Læger
- Vol. 188 (14) , 1-6
Open AccessPresent and future use of point-of-care testing
The use of point-of-care testing (POCT) for patient-based biochemical measurements in blood is growing rapidly, and the number will likely increase dramatically outside hospitals in the coming years due to healthcare reform and pressure on various healthcare sectors. This literature review finds that it calls for attention to the analysis performance and its limitations, as well as with the skills of the equipment users (including citizens). The Danish Institute for Quality in Healthcare has recommended that national standards for the quality assurance of POCT be established, and we, as laboratories, would be happy to help identify which areas requires national standardisation.
- 26 September 2025
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 63 (3) , 250-257
Preanalytical stability of zinc in whole blood serum and plasma tubes as measured by ICP-OES and colourimetry
Background: Zinc deficiency is a global concern, particularly in low-income countries, but also among vulnerable groups in Western countries, such as children. Diagnosing mild or moderate zinc deficiency is however challenging because of nonspecific symptoms and due to circulating zinc showing only subtle changes, requiring high accuracy in measurement. Challenges to accurate measurement include variations from choice of analytical instrument, analysis performance, and preanalytical factors such as choice of sample matrices and delayed blood sample processing. This study aimed to examine the stability of zinc in plasma and serum, measured by the recommended inductively coupled plasma optical emission spectrometry (ICP-OES) method and a direct colourimetric assay on the fully automated Roche Cobas c702 analyzer. Methods: A total of 245 whole blood samples were stored at room temperature for 0–8 h after blood sampling, then centrifuged for 10 min at 2000 g (serum) or 5 min at 2650 g (plasma), frozen at −20°C, and analysed, respectively, on ICP-OES and Cobas, the latter with the colourimetric kit from Sentinel diagnostics. Results: Serum zinc concentrations measured on Cobas and ICP-OES showed no statistically significant change up to 6 h and never exceeded acceptable limits. Plasma zinc concentrations increased steadily over time, exceeding acceptable limits after 6 h. There were statistically significant differences between zinc measurements on ICP-OES and Cobas in both serum and plasma. Conclusions: Zinc is stable for at least 8 h in serum and up to 6 h in plasma when measured by either Sentinel diagnostic colourimetric method on Cobas or ICP-OES.
- 26 September 2025
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 63 (3) , 250-257
Preanalytical stability of zinc in whole blood serum and plasma tubes as measured by ICP-OES and colourimetry
Background: Zinc deficiency is a global concern, particularly in low-income countries, but also among vulnerable groups in Western countries, such as children. Diagnosing mild or moderate zinc deficiency is however challenging because of nonspecific symptoms and due to circulating zinc showing only subtle changes, requiring high accuracy in measurement. Challenges to accurate measurement include variations from choice of analytical instrument, analysis performance, and preanalytical factors such as choice of sample matrices and delayed blood sample processing. This study aimed to examine the stability of zinc in plasma and serum, measured by the recommended inductively coupled plasma optical emission spectrometry (ICP-OES) method and a direct colourimetric assay on the fully automated Roche Cobas c702 analyzer. Methods: A total of 245 whole blood samples were stored at room temperature for 0–8 h after blood sampling, then centrifuged for 10 min at 2000 g (serum) or 5 min at 2650 g (plasma), frozen at −20°C, and analysed, respectively, on ICP-OES and Cobas, the latter with the colourimetric kit from Sentinel diagnostics. Results: Serum zinc concentrations measured on Cobas and ICP-OES showed no statistically significant change up to 6 h and never exceeded acceptable limits. Plasma zinc concentrations increased steadily over time, exceeding acceptable limits after 6 h. There were statistically significant differences between zinc measurements on ICP-OES and Cobas in both serum and plasma. Conclusions: Zinc is stable for at least 8 h in serum and up to 6 h in plasma when measured by either Sentinel diagnostic colourimetric method on Cobas or ICP-OES.
- 19 May 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 85 (4) , 275-280
Validation of cobas ® pulse point-of-care testing device for blood glucose monitoring
The aim of this study was to validate the blood glucose point-of-care system, cobas® pulse (Roche Diagnostics GmbH), which is the successor to the Accu-Chek® Inform II system (Roche Diagnostics GmbH). Since the cobas® pulse device is intended to replace an existing device from the same manufacturer, we found it highly relevant to perform an industry-independent validation regarding accuracy and comparability with existing glucose measurement systems. From 40 randomly selected, non-fasting adults capillary and venous blood was drawn simultaneously. Correlation and agreement was evaluated by comparing capillary blood glucose on cobas® pulse to plasma glucose on cobas® 8000 (Roche Diagnostics GmbH) and capillary blood glucose on ABL800 Flex (Radiometer, Denmark), respectively. The cobas® pulse generally showed good agreement with both comparison methods, although the agreement between cobas® pulse and ABL800 Flex was better (bias -0.01 mmol/L) than between cobas® pulse and cobas® 8000 (bias 0.61 mmol/L). Differences between measurements of low blood glucose levels (range 0.5 to 4.8 mmol/L) and higher blood glucose levels (range 9.7 to 15.3 mmol/L) when comparing cobas® pulse to ABL800 Flex was also within allowable limits. Altogether, the validation study demonstrated a clinically satisfactory performance of the cobas® pulse point-of-care device.
- 19 May 2025
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 85 (4) , 275-280
Validation of cobas ® pulse point-of-care testing device for blood glucose monitoring
The aim of this study was to validate the blood glucose point-of-care system, cobas® pulse (Roche Diagnostics GmbH), which is the successor to the Accu-Chek® Inform II system (Roche Diagnostics GmbH). Since the cobas® pulse device is intended to replace an existing device from the same manufacturer, we found it highly relevant to perform an industry-independent validation regarding accuracy and comparability with existing glucose measurement systems. From 40 randomly selected, non-fasting adults capillary and venous blood was drawn simultaneously. Correlation and agreement was evaluated by comparing capillary blood glucose on cobas® pulse to plasma glucose on cobas® 8000 (Roche Diagnostics GmbH) and capillary blood glucose on ABL800 Flex (Radiometer, Denmark), respectively. The cobas® pulse generally showed good agreement with both comparison methods, although the agreement between cobas® pulse and ABL800 Flex was better (bias -0.01 mmol/L) than between cobas® pulse and cobas® 8000 (bias 0.61 mmol/L). Differences between measurements of low blood glucose levels (range 0.5 to 4.8 mmol/L) and higher blood glucose levels (range 9.7 to 15.3 mmol/L) when comparing cobas® pulse to ABL800 Flex was also within allowable limits. Altogether, the validation study demonstrated a clinically satisfactory performance of the cobas® pulse point-of-care device.
- Open Access
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 972-978
Knowledge among clinical personnel on the impact of hemolysis using blood gas analyzers
Objectives: In the light of a rapidly increasing use of POCT blood gas testing, where tests and interpretation are performed by non-laboratory personnel, the objective was to investigate the knowledge among personnel in the Nordic countries using blood gas analyzers with focus on the interference from hemolysis. Methods: Information was obtained from a self-developed, pre-tested online questionnaire. The questions covered demographic information about the respondents and specific questions on handling of and knowledge about blood gas analyses and the impact of hemolysis. The questionnaire was distributed by e-mail to relevant colleagues on behalf of the Nordic preanalytical scientific working group under the Nordic Federation of Clinical Chemistry. Results: A total of 117 respondents completed the questionnaire. 62.7 % respondents both used the analyzer and interpreted the results. 59.6 % respondents did not know to which degree the blood gas analyzer can identify hemolysis. 4.4 % answered that all levels or high levels of hemolysis can be detected. 3.9 % considered the result valid despite hemolysis if it is released from the instrument. 73.7 % of all respondents knew that hemolysis alters potassium measurements, while knowledge about the effect on PaO2 and bicarbonate measurements were more divergent. Conclusions: The knowledge about blood gas analyzers with focus on the interference from hemolysis is sparse among non-laboratory personnel using the blood gas analyzers. This emphasizes the need for better education and competence management, which perhaps is even more important for these analyses than for other point-of-care tests.
- 11 December 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (5) , 972-978
Open AccessKnowledge among clinical personnel on the impact of hemolysis using blood gas analyzers
Objectives: In the light of a rapidly increasing use of POCT blood gas testing, where tests and interpretation are performed by non-laboratory personnel, the objective was to investigate the knowledge among personnel in the Nordic countries using blood gas analyzers with focus on the interference from hemolysis. Methods: Information was obtained from a self-developed, pre-tested online questionnaire. The questions covered demographic information about the respondents and specific questions on handling of and knowledge about blood gas analyses and the impact of hemolysis. The questionnaire was distributed by e-mail to relevant colleagues on behalf of the Nordic preanalytical scientific working group under the Nordic Federation of Clinical Chemistry. Results: A total of 117 respondents completed the questionnaire. 62.7 % respondents both used the analyzer and interpreted the results. 59.6 % respondents did not know to which degree the blood gas analyzer can identify hemolysis. 4.4 % answered that all levels or high levels of hemolysis can be detected. 3.9 % considered the result valid despite hemolysis if it is released from the instrument. 73.7 % of all respondents knew that hemolysis alters potassium measurements, while knowledge about the effect on PaO2 and bicarbonate measurements were more divergent. Conclusions: The knowledge about blood gas analyzers with focus on the interference from hemolysis is sparse among non-laboratory personnel using the blood gas analyzers. This emphasizes the need for better education and competence management, which perhaps is even more important for these analyses than for other point-of-care tests.
- Open Access
- 11 November 2024
- Published by Taylor & Francis in Scandinavian Journal of Primary Health Care
- Vol. 43 (2) , 260-269
Validation of point-of-care tests used at in-home assessments among older adults in primary care
Diagnosing acute disease in older adults is challenged by vague and atypical symptoms. Point-of-care tests (POCTs) at home may improve diagnostics and clinical decision-making. We compared various POCT devices to routine testing in acutely ill older adults to assess their clinical reliability. We enrolled participants aged 65+ years requiring acute in-home assessment with signs of acute conditions. Venous and capillary blood samples were collected and analysed on-site using POCT, while identical samples were transported and analysed in a routine laboratory. Agreement between POCT and laboratory testing was assessed using scatter plots with linear regression, Pearson's correlation coefficient (PCC), limits of agreement, and Bland-Altman plots. Misclassification rates were calculated based on clinically meaningful cut-offs to assess POCT's clinical reliability. We included 100 participants with a mean age of 81.6 (±8.4 SD) years. Strong correlation was found between POCT and routine measurements (PCC: 0.76-0.94 for capillary samples and 0.85-0.98 for venous samples). Venous samples showed higher PCC than capillary, except for neutrophils (0.93 for capillary, 0.89 for venous). Misclassification occurred in capillary samples for haemoglobin (10/62) and total WBC (6/50), while in venous samples, misclassification was observed for haemoglobin (4/54), total WBC (4/50), K+ (5/47), urea (5/47), and creatinine (3/42). No misclassification was observed for Na+. POCT provides acceptable, clinically reliable measurements in acutely ill older adults, potentially enhancing diagnostics and treatments during in-home assessment. Venous blood testing is preferable due to a lower misclassification rate, but capillary blood remains a pragmatic alternative, despite higher variation and inaccuracy.
- 11 November 2024
- Published by Taylor & Francis in Scandinavian Journal of Primary Health Care
- Vol. 43 (2) , 260-269
Open AccessValidation of point-of-care tests used at in-home assessments among older adults in primary care
Diagnosing acute disease in older adults is challenged by vague and atypical symptoms. Point-of-care tests (POCTs) at home may improve diagnostics and clinical decision-making. We compared various POCT devices to routine testing in acutely ill older adults to assess their clinical reliability. We enrolled participants aged 65+ years requiring acute in-home assessment with signs of acute conditions. Venous and capillary blood samples were collected and analysed on-site using POCT, while identical samples were transported and analysed in a routine laboratory. Agreement between POCT and laboratory testing was assessed using scatter plots with linear regression, Pearson's correlation coefficient (PCC), limits of agreement, and Bland-Altman plots. Misclassification rates were calculated based on clinically meaningful cut-offs to assess POCT's clinical reliability. We included 100 participants with a mean age of 81.6 (±8.4 SD) years. Strong correlation was found between POCT and routine measurements (PCC: 0.76-0.94 for capillary samples and 0.85-0.98 for venous samples). Venous samples showed higher PCC than capillary, except for neutrophils (0.93 for capillary, 0.89 for venous). Misclassification occurred in capillary samples for haemoglobin (10/62) and total WBC (6/50), while in venous samples, misclassification was observed for haemoglobin (4/54), total WBC (4/50), K+ (5/47), urea (5/47), and creatinine (3/42). No misclassification was observed for Na+. POCT provides acceptable, clinically reliable measurements in acutely ill older adults, potentially enhancing diagnostics and treatments during in-home assessment. Venous blood testing is preferable due to a lower misclassification rate, but capillary blood remains a pragmatic alternative, despite higher variation and inaccuracy.
- Open Access
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e033493
DANSPOT: A Multicenter Stepped‐Wedge Cluster‐Randomized Trial of the Reclassification of Acute Myocardial Infarction: Rationale and Study Design
Background: Cardiac troponins are the preferred biomarkers for the diagnosis of acute myocardial infarction. Although sex‐specific 99th percentile thresholds of troponins are recommended in international guidelines, the clinical effect of their use is poorly investigated. The DANSPOT Study (The Danish Study of Sex‐ and Population‐Specific 99th percentile upper reference limits of Troponin) aims to evaluate the clinical effect of a prospective implementation of population‐ and sex‐specific diagnostic thresholds of troponins into clinical practice. Methods: This study is a nationwide, multicenter, stepped‐wedge cluster‐randomized trial of the implementation of population‐ and sex‐specific thresholds of troponins in 22 of 23 clinical centers in Denmark. We established sex‐specific thresholds for 5 different troponin assays based on troponin levels in a healthy Danish reference population. Centers will sequentially cross over from current uniform manufacturer‐derived thresholds to the new population‐ and sex‐specific thresholds. The primary cohort is defined as patients with symptoms suggestive of acute coronary syndrome having at least 1 troponin measurement performed within 24 hours of arrival with a peak troponin value between the current uniform threshold and the new sex‐specific female and male thresholds. The study will compare the occurrence of the primary outcome, defined as a composite of nonfatal myocardial infarction, unplanned revascularization, and all‐cause mortality within 1 year, separately for men and women before and after the implementation of the new sex‐specific thresholds. Conclusions: The DANSPOT Study is expected to show the clinical effects on diagnostics, treatment, and clinical outcomes in patients with myocardial infarction of implementing sex‐specific diagnostic thresholds for troponin based on a national Danish reference population. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05336435.
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e033493
Open AccessDANSPOT: A Multicenter Stepped‐Wedge Cluster‐Randomized Trial of the Reclassification of Acute Myocardial Infarction: Rationale and Study Design
Background: Cardiac troponins are the preferred biomarkers for the diagnosis of acute myocardial infarction. Although sex‐specific 99th percentile thresholds of troponins are recommended in international guidelines, the clinical effect of their use is poorly investigated. The DANSPOT Study (The Danish Study of Sex‐ and Population‐Specific 99th percentile upper reference limits of Troponin) aims to evaluate the clinical effect of a prospective implementation of population‐ and sex‐specific diagnostic thresholds of troponins into clinical practice. Methods: This study is a nationwide, multicenter, stepped‐wedge cluster‐randomized trial of the implementation of population‐ and sex‐specific thresholds of troponins in 22 of 23 clinical centers in Denmark. We established sex‐specific thresholds for 5 different troponin assays based on troponin levels in a healthy Danish reference population. Centers will sequentially cross over from current uniform manufacturer‐derived thresholds to the new population‐ and sex‐specific thresholds. The primary cohort is defined as patients with symptoms suggestive of acute coronary syndrome having at least 1 troponin measurement performed within 24 hours of arrival with a peak troponin value between the current uniform threshold and the new sex‐specific female and male thresholds. The study will compare the occurrence of the primary outcome, defined as a composite of nonfatal myocardial infarction, unplanned revascularization, and all‐cause mortality within 1 year, separately for men and women before and after the implementation of the new sex‐specific thresholds. Conclusions: The DANSPOT Study is expected to show the clinical effects on diagnostics, treatment, and clinical outcomes in patients with myocardial infarction of implementing sex‐specific diagnostic thresholds for troponin based on a national Danish reference population. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05336435.
- Open Access
- 26 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2554
No Detectable Differences in microRNA Plasma Levels between Diabetic Hypertensive Patients with and without Incident Subclinical Atrial Fibrillation
Background: Long-term rhythm monitoring (LTRM) can detect undiagnosed atrial fibrillation (AF) in patients at risk of AF and stroke. Circulating microRNAs (miRNAs), which have been shown to play a role in atrial electrical and structural remodelling, could help to select patients who would benefit most from LTRM. The aim of this study was to investigate whether patients with diabetes mellitus (DM) and hypertension and screen-detected subclinical AF (SCAF) using an insertable cardiac monitor (ICM) have significantly different plasma baseline levels of five selected miRNAs playing a role in the modulation of atrial electrical and structural remodelling (miR-21-5p, miR-29b-3p, miR-150-5p, miR-328-3p, and miR-432-5p) compared to those without SCAF. Methods: This study was performed at the outpatient clinic of a secondary academic teaching hospital between December 2013 and November 2015. Eligible patients were ≥65 years of age with DM and hypertension but without known heart diseases. All patients received an ICM. On the day of ICM implantation, blood samples for the measurement of plasma levels of the five miRNAs were drawn. In this post hoc analysis, we investigated their expression by reverse transcription-quantitative polymerase chain reaction. MiRNA plasma levels in patients with and without newly detected SCAF were compared. Results: We included 82 consecutive patients (median age of 71.3 years (IQR 67.4–75.1)), who were followed for a median of 588 days (IQR: 453–712 days). Seventeen patients (20.7%) had ICM-detected SCAF. Plasma levels of miR-328-3p, miR-29b-3p, miR-21-5p, miR-432-5p, and miR-150-5p were slightly but not significantly different in patients with incident SCAF compared with patients without. Conclusions: In patients with hypertension and DM, newly detected SCAF was not significantly associated with changes in expression levels of miR-21-5p, miR-29b-3p, miR-150-5p, miR-328-3p, and miR-432-5p.
- 26 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2554
Open AccessNo Detectable Differences in microRNA Plasma Levels between Diabetic Hypertensive Patients with and without Incident Subclinical Atrial Fibrillation
Background: Long-term rhythm monitoring (LTRM) can detect undiagnosed atrial fibrillation (AF) in patients at risk of AF and stroke. Circulating microRNAs (miRNAs), which have been shown to play a role in atrial electrical and structural remodelling, could help to select patients who would benefit most from LTRM. The aim of this study was to investigate whether patients with diabetes mellitus (DM) and hypertension and screen-detected subclinical AF (SCAF) using an insertable cardiac monitor (ICM) have significantly different plasma baseline levels of five selected miRNAs playing a role in the modulation of atrial electrical and structural remodelling (miR-21-5p, miR-29b-3p, miR-150-5p, miR-328-3p, and miR-432-5p) compared to those without SCAF. Methods: This study was performed at the outpatient clinic of a secondary academic teaching hospital between December 2013 and November 2015. Eligible patients were ≥65 years of age with DM and hypertension but without known heart diseases. All patients received an ICM. On the day of ICM implantation, blood samples for the measurement of plasma levels of the five miRNAs were drawn. In this post hoc analysis, we investigated their expression by reverse transcription-quantitative polymerase chain reaction. MiRNA plasma levels in patients with and without newly detected SCAF were compared. Results: We included 82 consecutive patients (median age of 71.3 years (IQR 67.4–75.1)), who were followed for a median of 588 days (IQR: 453–712 days). Seventeen patients (20.7%) had ICM-detected SCAF. Plasma levels of miR-328-3p, miR-29b-3p, miR-21-5p, miR-432-5p, and miR-150-5p were slightly but not significantly different in patients with incident SCAF compared with patients without. Conclusions: In patients with hypertension and DM, newly detected SCAF was not significantly associated with changes in expression levels of miR-21-5p, miR-29b-3p, miR-150-5p, miR-328-3p, and miR-432-5p.
- 22 April 2024
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 84 (3) , 174-182
Critical test result management at Danish hospital laboratories: a national survey
Critical test results in clinical laboratories are crucial for timely patient care, serving as indicators of potentially life-threatening conditions. Despite their importance, a notable heterogeneity in management practices exists globally. This study investigates the current practices of managing critical results at Danish clinical biochemistry laboratories and identifies areas prone for improvement. A comprehensive online survey was distributed to all 21 Danish clinical biochemistry laboratories regarding their critical result management, including documentation practices, critical limit selection, and quality assurance measures. A total of 17 laboratories (81%) responded. The answers revealed a generally uniform approach to managing critical results, with all laboratories having 24-h reporting, local instructions and using the telephone as communication channel. However, variations were noted in documentation practices and critical limit selection. Notably, 23.5% of the laboratories reported that one out of every ten critical results was not reported, indicating a significant risk of delayed critical results. This is further complicated by the limited use of predefined timeframes for reporting and also, only few laboratories actively monitored response times. The findings emphasize the need for more standardized documentation and evaluation practices to align with international standards and to enhance patient safety. While the laboratories showed a commitment to standardized procedures, the study emphasizes the necessity of a National or Nordic guideline to supplement the ISO 15189:2022. This study is a step towards optimizing critical result management, not only in Danish clinical biochemistry laboratories but also across various laboratory specialties, thereby improving overall laboratory quality, efficiency, and patient safety.
- 22 April 2024
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 84 (3) , 174-182
Critical test result management at Danish hospital laboratories: a national survey
Critical test results in clinical laboratories are crucial for timely patient care, serving as indicators of potentially life-threatening conditions. Despite their importance, a notable heterogeneity in management practices exists globally. This study investigates the current practices of managing critical results at Danish clinical biochemistry laboratories and identifies areas prone for improvement. A comprehensive online survey was distributed to all 21 Danish clinical biochemistry laboratories regarding their critical result management, including documentation practices, critical limit selection, and quality assurance measures. A total of 17 laboratories (81%) responded. The answers revealed a generally uniform approach to managing critical results, with all laboratories having 24-h reporting, local instructions and using the telephone as communication channel. However, variations were noted in documentation practices and critical limit selection. Notably, 23.5% of the laboratories reported that one out of every ten critical results was not reported, indicating a significant risk of delayed critical results. This is further complicated by the limited use of predefined timeframes for reporting and also, only few laboratories actively monitored response times. The findings emphasize the need for more standardized documentation and evaluation practices to align with international standards and to enhance patient safety. While the laboratories showed a commitment to standardized procedures, the study emphasizes the necessity of a National or Nordic guideline to supplement the ISO 15189:2022. This study is a step towards optimizing critical result management, not only in Danish clinical biochemistry laboratories but also across various laboratory specialties, thereby improving overall laboratory quality, efficiency, and patient safety.
- Open Access
- 30 March 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 170, 111337
Considerations for the use of biochemical laboratory registry data in clinical and public health research
- 30 March 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 170, 111337
Open AccessConsiderations for the use of biochemical laboratory registry data in clinical and public health research